SCHEMBL24373906

SCHEMBL24373906

Cc1cc2cn[nH]c2c(B2OC(C)(C)C(C)(C)O2)c1C

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.34
TRPA1 O75762 2/20 0.34
HTT P42858 1/20 0.31
PTK2 Q05397 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29479125 1.00 MAPT (0.34) MAPTTRPA1HTTPTK2
SCHEMBL27096244 0.86 TRPA1 (0.33) MAPTTRPA1HTT
SCHEMBL29479128 0.86 TRPA1 (0.33) MAPTTRPA1HTT
SCHEMBL27096469 0.86 NOS1 (0.34) TRPA1
SCHEMBL29468945 0.81 MAPT (0.49) MAPTTRPA1HTT
SCHEMBL21379213 0.81 MAPT (0.49) MAPTTRPA1HTT
SCHEMBL31620771 0.78 TRPA1 (0.40) MAPTTRPA1
SCHEMBL20085466 0.78 TRPA1 (0.40) MAPTTRPA1
SCHEMBL24553739 0.75 TRPA1 (0.32) MAPTTRPA1
SCHEMBL15288252 0.72 TRPA1 (0.39) MAPTTRPA1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. 2024-02-22 US disclosed
WO-2022083569-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE KRAS, HRAS, APC MAPT 4629/4885TRPA1 2951/4885HTT 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.